About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Court Report | Main | FDA FY2012 Drug Approvals Equal FY2011 Mark »

January 21, 2013

Comments

Don,

Nice job on compiling the table of fees. Our clients are just going to love hearing about all these fees and how most are going UP.

Thanks Don. I especially like the 2nd RCE fee - it's like the US equivalent of EPO renewal fees that have to be paid while the EPO sits on its hands not examining the application. What if half the cost of the second RCE came out of the examiner's salary? I think that would put an end to poor examination. But God forbid the PTO admit that some (many) of its examiners are incompetent, deliberately unhelpful, rude, or just plain sadists.

I love how the fees beign set on a below cost basis are going up. How can that be if the PTO had money for Congress to pilfer in the past? Is it because they are spending more to increase capacity/reduce the backlog and develop a reserve? I wrote about their "justifications" for charging high fees for RCEs and Appeals ....

I expect this RCE price increase is related to how companies may try to extend patent coverage times with RCEs -- see Exelixis v. Kappos. Seems sensible to me.

The comments to this entry are closed.

March 2025

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31